RELEVANT EVENT

Pursuant to the provisions of article 82 of the Spanish Securities Market Act (*Ley del Mercado de Valores*), Grifols, S.A. ("Grifols") informs about the signature yesterday in San Francisco (US) of a definitive agreement with Alkahest, a company based in Redwood City, California (US), whereby Grifols will make a major equity investment in Alkahest and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging and other disorders of the central nervous system (CNS), including Alzheimer’s.

Grifols will make a $37.5 million equity investment in the form of a cash payment in exchange for 45% of Alkahest's shares following the closing of the transaction. In addition, Grifols will provide a further payment of $12.5 million and fund the development of plasma-based products, which will be commercialized by Grifols throughout the world. Alkahest will receive milestone payments and royalties on sales of such products by Grifols.

Grifols will have two seats on Alkahest's Board of Directors and will collaborate with Alkahest researchers through the creation of a Scientific Joint Steering Committee.

Alkahest is a privately held biopharmaceutical company founded in 2014 by the scientist Tony Wyss-Coray PhD and other leading scientists at Stanford University (US) who demonstrated at Stanford University that factors in the blood of young animals were able to restore mental capabilities in old animals.

The transaction is part of Grifols’ commitment with the research and development of therapeutic alternatives designed to contribute to both scientific and social development. In addition, it is aligned with Grifols' strategy of complementing its range of existing plasma protein therapies and diagnostic products to treat and diagnose serious diseases and to extend the quality of human life.

Barcelona, on 4 March 2015

Raimon Grifols Roura
Secretary to the Board of Directors